Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Apr

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Analysis Shows Nearly 7 Percent of Global Clinical Trials Are Impacted by Middle East Conflict

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer

Ablative Radiotherapy May Improves Outcomes for Patients With Large Intrahepatic Cholangiocarcinoma

Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant